Two New Manufacturer Notices to 340B Entities on HRSA Website

The generic drug manufacturer recently required to repay covered entities for charging above the ceiling price following an audit has posted a notice on the U.S. Health Services and Resources Administration (HRSA) website about recalculation of ceiling prices and “potential payment” of “eligible refunds.”

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content

*Sign up for news summaries and alerts from 340B Report